Your Trusted Source for Information on Health
HSDD Hypoactive Sexual Desire Disorder
According to sexual scientific studies, approximately 10 to 25% of women have what is commonly referred to as a deficient or decreased libido, basically their desire for sex if very low. Reasons for this may vary including relationship and or self image issues. But some doctors relate this in some to a chemical imbalance in their brain. Flibanserin is a new trial medication for HSDD (Hypoactive Sexual Desire Disorder) in women and is being touted by some as the “female viagra®”. Flibanserin was produced by Boehringer Ingelheim, a German pharmaceutical company. It was recently purchased by Sprout Pharmaceuticals and once the FDA approved it was given the trade name: Addyi® It is a serotonin receptor agonist and was created and tested as an antidepressant but did not do well as such. During its testing for depression, many of the female patients interestingly reported an increase in their sexual desire and arousal. This led them to test it for this exact purpose.
In clinical stage three trials of the drug, it was reported that over 2000 female test subjects took part and its finding where encouraging. The patients before the testing began had an average of 2.8 times a month where they considered themselves to have had a satisfactory sexual experience. During the testing, this number rose to 4.5 times a month. The placebo group reported a rise as well but to the lesser extent of 3.7. Some of the side effects reported in testing of Flibanserin where headache, fatigue, dizziness, urinary infections, sinusitis and diarrhea. But for some woman, these side may not exist or only some and maybe considered acceptable with the improvement in their sexual life.
Unlike the male erectile dysfunction drugs on the market that can be taken on a “as needed basis”, Flibanserin has to be taken on a daily basis and for what looks like three to six weeks to be working fully. Some say that Flibanserin also holds more promise than another female sexual disorder remedy Intrinsa® due to Intrinsa® typically only being prescribed to post menopausal woman. Flibanserin also does not affect hormonal levels like Intrinsa® does.
Some controversy has developed from a result of these findings. Some say that pharmaceutical companies are pushing drugs on the population as a cure to any female sexual dissatisfaction. They say that a pill will not deal with other underlying issues of female sexual problems that are often the case such as a non loving partner, psychological issues, stress, poor self image, emotional issues etc. There could also be other hidden things that would be better for partners to talk about and make their relationship better. What works for men does not work for woman, sexual dysfunction for men can mean an entirely different thing than sexual dysfunction in women. Women are more complicated in this area, generally speaking, men don't need intimacy, where as women do. No pill will solve that issue. Regardless we will wait and see what becomes of this trial drug... Now we know, news was released in mid 2010 that stated that the FDA rejected this treatment and as a result the company a few months later decided to completely stop research with it. News... August 18th 2015 the FDA approved Addyi® (flibanserin) for the treatment hypo sexual desire disorder in women.
Visit webmd's guide to reviving a womans sex drive.
Copyright 2003-2010 Healthreserve.com All Rights Reserved.
All images remain property of their respective owners.